CSM-101

CSM-101 is an orally available, first-in-class small molecule developed to restore lysosomal function by activating TRPML1 (transient receptor potential mucolipin 1), a critical lysosomal ion channel protein. Lysosomes are cellular organelles responsible for breaking down waste and damaged components within cells. Dysfunction of lysosomes, particularly due to GBA1 mutations, is implicated in the pathogenesis of Gaucher’s disease and Parkinson’s disease by promoting toxic alpha-synuclein accumulation and neurodegeneration. By activating TRPML1, CSM-101 aims to correct this dysfunction, reduce toxic lipid buildup and neuroinflammation, lower alpha-synuclein levels, preserve dopaminergic neurons, and potentially modify disease progression. Preclinical studies have shown that CSM-101 achieves high central nervous system exposure with favorable safety and pharmacokinetic profiles. The drug is being developed initially for Gaucher’s patients with Parkinson’s disease but may expand into broader GBA-associated or idiopathic Parkinson's populations[1][2][3][4][9].